Loading…
Kronox Lab Sciences (KRONOX)₹193.51+2.33%Specialty Chemicals
In the Mar 2026 quarter (standalone), Kronox Lab Sciences reported sales of ₹26.20 Cr, up 0.0% from Mar 2025, and net profit of ₹7.98 Cr, up 26.5% year on year. For the year to Mar 2026, sales were ₹101 Cr and net profit ₹27.94 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 26.01 | 21.07 | 20.76 | 22.23 | 25.23 | 24.91 | 24.07 | 26.20 | 24.35 | 25.59 | 25.33 | 26.20 |
| Expenses | 17.45 | 15.17 | 14.64 | 14.35 | 16.99 | 16.08 | 15.67 | 18.39 | 16.33 | 16.91 | 17.26 | 16.63 |
| Operating Profit | 8.51 | 5.85 | 6.07 | 7.84 | 8.20 | 8.81 | 8.35 | 7.74 | 7.96 | 8.64 | 8.02 | 9.51 |
| OPM % | 32.9% | 27.9% | 29.4% | 35.5% | 32.7% | 35.5% | 34.9% | 29.7% | 32.9% | 34.0% | 31.9% | 36.5% |
| Other Income | 0.25 | 0.50 | 0.03 | 0.84 | 0.44 | 0.37 | 0.83 | 0.92 | 0.88 | 1.05 | 1.14 | 2.16 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 | 0.03 |
| Depreciation | 0.31 | 0.37 | 0.29 | 0.28 | 0.32 | 0.33 | 0.35 | 0.34 | 0.39 | 0.46 | 0.51 | 0.65 |
| Profit before tax | 8.45 | 5.98 | 5.81 | 8.40 | 8.32 | 8.83 | 8.83 | 8.32 | 8.45 | 9.19 | 8.61 | 10.99 |
| Tax % | 24.4% | 27.0% | 18.2% | 29.8% | 25.9% | 26.6% | 26.0% | 24.0% | 25.7% | 27.2% | 23.3% | 26.9% |
| Net Profit | 6.37 | 4.34 | 4.73 | 5.87 | 6.14 | 6.46 | 6.52 | 6.31 | 6.27 | 6.66 | 6.58 | 7.98 |
| EPS (Rs) | 1.71 | 1.16 | 1.27 | 1.57 | 1.65 | 1.73 | 1.75 | 1.69 | 1.68 | 1.79 | 1.77 | 2.15 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales | 50.09 | 62.07 | 82.19 | 96.21 | 90.19 | 100 | 101 | 101 |
| Expenses | 39.04 | 48.05 | 63.06 | 74.10 | 62.07 | 67.05 | 67.08 | 67.13 |
| Operating Profit | 12.01 | 14.98 | 19.99 | 21.97 | 27.97 | 32.99 | 33.99 | 34.13 |
| OPM % | 23.1% | 24.1% | 24.1% | 23.1% | 32.1% | 33.1% | 34.1% | 33.6% |
| Other Income | 1.01 | 1.01 | 1.01 | 2.01 | 2.01 | 3.01 | 5.02 | 5.23 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.09 |
| Depreciation | 0.99 | 1.99 | 1.99 | 1.99 | 0.99 | 0.99 | 1.99 | 2.01 |
| Profit before tax | 12.01 | 13.02 | 18.03 | 22.01 | 29.03 | 34.04 | 37.06 | 37.24 |
| Tax % | 26.9% | 25.9% | 26.0% | 25.9% | 24.9% | 25.9% | 25.9% | — |
| Exceptional items | 0.00 | 0.03 | 0.03 | 0.02 | 0.00 | 0.00 | 0.00 | — |
| Net Profit | 8.98 | 9.99 | 13.97 | 15.97 | 20.98 | 24.95 | 27.94 | 27.49 |
| EPS (Rs) | 342.84 | 402.73 | 564.94 | 4.41 | 5.74 | 6.84 | 7.44 | 7.39 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 8.9% | 7.0% | 7.0% | — |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.24 | 0.23 | 0.23 | 36.89 | 36.88 | 36.89 | 36.86 |
| Reserves | 22.95 | 26.95 | 39.94 | 7.98 | 28.94 | 52.88 | 78.79 |
| Borrowings | 0.00 | 3.99 | 2.99 | 0.00 | 0.00 | 0.00 | 1.99 |
| Other Liabilities | 10.95 | 6.97 | 12.94 | 8.96 | 7.96 | 8.96 | 9.95 |
| Total Liabilities | 33.89 | 37.90 | 56.86 | 53.83 | 73.78 | 98.73 | 128 |
| Fixed Assets | 5.99 | 8.98 | 10.98 | 15.96 | 25.94 | 27.97 | 28.94 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.99 | 0.99 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 28.90 | 27.92 | 44.88 | 37.87 | 46.84 | 69.77 | 97.66 |
| Inventories | 5.05 | 5.50 | 7.52 | 9.18 | 9.27 | 6.38 | 8.38 |
| Trade receivables | 15.18 | 15.43 | 25.76 | 18.52 | 17.62 | 19.87 | 21.18 |
| Cash & equivalents | 2.49 | 2.06 | 2.82 | 3.57 | 3.65 | 8.45 | 48.80 |
| Total Assets | 33.89 | 37.90 | 56.86 | 53.83 | 73.78 | 98.73 | 128 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from operating activity | 4.01 | 11.02 | 9.02 | 20.05 | 17.05 | 31.08 | 24.04 |
| Cash from investing activity | −4.01 | −3.01 | −8.03 | −7.02 | −17.06 | −28.09 | −24.09 |
| Cash from financing activity | 0.00 | −6.98 | −0.99 | −12.96 | 0.00 | −1.99 | 0.00 |
| Net cash flow | 0.00 | 0.99 | 0.99 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capex | 1.58 | 1.64 | 3.79 | 8.39 | 12.24 | 3.09 | 3.30 |
| Free cash flow | 2.99 | 9.98 | 4.99 | 10.98 | 4.99 | 27.95 | 20.95 |
| CFO / OP % | 65.0% | 100.0% | 69.9% | 116.9% | 87.0% | 120.0% | 98.0% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor days | 110 | 90 | 114 | 71 | 72 | 72 | 76 |
| Inventory days | 70 | 58 | 58 | 61 | 74 | 46 | 66 |
| Days payable | 102 | 69 | 89 | 52 | 51 | 52 | 52 |
| Cash conversion cycle | 79 | 80 | 85 | 81 | 95 | 67 | 91 |
| Working capital days | 101 | 96 | 123 | 84 | 144 | 169 | 72 |
| ROCE % | — | 50.1% | 51.1% | 50.1% | 52.1% | 44.1% | 36.1% |
For the Mar 2026 quarter, Kronox Lab Sciences reported sales of ₹26.20 Cr, up 0.0% year on year and net profit of ₹7.98 Cr, up 26.5% year on year. The operating margin was 36.5%.
Kronox Lab Sciences' sales for the year to Mar 2026 were ₹101 Cr; over the last twelve months they were ₹101 Cr.
Net profit for the year to Mar 2026 was ₹27.94 Cr, and ₹27.49 Cr over the last twelve months. Earnings per share over the same trailing period were ₹7.39.
Kronox Lab Sciences reported borrowings of ₹1.99 Cr at Mar 2026, against cash and equivalents of ₹48.80 Cr.
Cash from operations was ₹24.04 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹20.95 Cr.